BMRA
NASDAQBiomerica Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks21+400%
2025-11-022026-04-26
Mix1090d
- Other8(80%)
- SEC Filings2(20%)
Latest news
25 items- PRBiomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week® (DDW) 2026, to be held May 2–5, 2026, at McCormick Place in Chicago, Illinois. DDW is the world's largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, and related GI disciplines. Acceptance of this poster reflects the growing interest within the gastroenterology community in
- PRBiomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization PathwayThe Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica's certified laboratory partner that the test will be reviewed on an individual, claim-by-claim basis under Medicare's standard claims approval process.The Company's laboratory partner believes that properly documented claims — with appropriate diagnosis codes and evidence of medical necessity — are eligible for payment under existing $300 CMS payment rate. The inFoods® IBS test holds a dedicated CPT® Proprietary Laboratory Analyses (PLA) code and a CMS-established national payment rate of $300, prerequisites for Medicare claims submissions. Payment rates apply to claims appr
- PRBiomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally — Up to Five Million Canadians May Have IBS, Representing a Significant and Underserved Market Opportunity IRVINE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA) ("Biomerica" or the "Company"), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced the commercial launch of its inFoods® platform in Canada through two strategic partnerships: Phoenix Airmid Biomedical, which will serve as the exclus
- PRBiomerica Reports Third Quarter Fiscal 2026 Financial ResultsIRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), ("Biomerica" or the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026. Key Highlights: 1. inFoods® IBS Real-World Data: Nearly 60% of Irritable Bowel Syndrome ("IBS") Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with inFoods® IBS During the third quarter, Biomerica reported real-world data showing: 59.4% of patients achieved ≥30% reduction in abdominal pain68.1% achieved ≥30% reduction in bloating — using the FDA-recognized responde
- SECSEC Form 10-Q filed by Biomerica Inc.10-Q - BIOMERICA INC (0000073290) (Filer)
- PRBiomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in EuropeFirst Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe.Strategic Account: This new lab's scale and geographic reach across Europe positions it as a reference account and potential gateway to broader EU laboratory channel adoption.Repeat Order Potential: Based on the nature of the relationship, Biomerica believes this initial order will result in recurring orders as Hp Detect™ is integrated into the customer's routine testing workflow.Disease Burden: H. pylori affects an estimated 45% of the population across Europe's five largest countries. The WHO designates H. py
- PRBiomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great BritainUK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics. IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced that it has receiv
- SECSEC Form S-8 filed by Biomerica Inc.S-8 - BIOMERICA INC (0000073290) (Filer)
- PRBiomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS TherapyKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo
- PRVietnam Approves Biomerica's EZ Detect™ for Nationwide DistributionApproval Marks Biomerica's Strategic Entry into Southeast Asia's Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is working with a major healthcare products distributor in Vietnam who will manage the sales and distribution of the product through pharmacies, hospitals, physician's offices, and
- INSIDERDirector Chin Eric was granted 22,500 shares, increasing direct ownership by 225% to 32,500 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- SECSEC Form 10-Q filed by Biomerica Inc.10-Q - BIOMERICA INC (0000073290) (Filer)
- INSIDERChief Financial Officer Lu Gary was granted 40,000 shares, increasing direct ownership by 206% to 59,375 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERExecutive Vice-Chairman Barbieri Allen was granted 30,000 shares, increasing direct ownership by 127% to 53,543 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERDirector Gary M. Huff was granted 20,000 shares (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERChief Executive Officer Irani Zackary S. was granted 52,500 shares, increasing direct ownership by 33% to 211,320 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- INSIDERDirector Moatazedi David was granted 20,000 shares, increasing direct ownership by 188% to 30,625 units (SEC Form 4)4 - BIOMERICA INC (0000073290) (Issuer)
- PRBiomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS TestCMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS. IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's inFoo
- SECBiomerica Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BIOMERICA INC (0000073290) (Filer)
- PREgyptian Drug Authority Authorizes Biomerica's Complete Screening Test PortfolioAuthorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection of conditions that are related to the most common cancers and chronic diseases • Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that the Egyptian Drug Authority (EDA) has granted authorization for Biomerica's complete portfolio of rapid tests, enabling broad access
- PRBiomerica Expands Contract Development and Manufacturing Services to Meet Growing Market DemandRising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica's updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical diagnostic solutions, today announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand. The Company is enhancing its capabilities to provide greater value and reliability of product development and manufacturing across the entire development lifecycle for diagnostic innovators worldwide. With more than 40 years of expertise in as
- SECSEC Form DEFA14A filed by Biomerica Inc.DEFA14A - BIOMERICA INC (0000073290) (Filer)
- SECSEC Form DEF 14A filed by Biomerica Inc.DEF 14A - BIOMERICA INC (0000073290) (Filer)
- PRHenry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica's Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, to market Biomerica's inFoods® Irritable Bowel Syndrome (IBS) test in the United States, excluding New York State. Henry Schein's powerful nationwide distribution network, comprised of m
- PRBiomerica Reports First Quarter Fiscal 2026 Financial ResultsReported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company's Ongoing Focus on Cost Reduction and Operational EfficiencyEarnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), ("Biomerica" or the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter ended August 31, 2025. Key Highlights: inFoods® IBS receives P
BMRA FAQ
5 questionsWhat does Biomerica Inc. do?
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its...Where does BMRA stock trade?
Biomerica Inc. (BMRA) is listed on NASDAQ.What sector and industry is BMRA in?
Biomerica Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What companies are similar to BMRA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), NNNN (Anbio Biotechnology), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.). Compare BMRA side-by-side with any of them on Quantisnow.How can I track BMRA on Quantisnow?
Quantisnow aggregates Biomerica Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BMRA to receive live email and push alerts on every new disclosure.